Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A
Nov 13, 2026, 23:06

Büşra Ece Günaydın: A New Approach to Factor VIII Gene Insertion for Hemophilia A

Büşra Ece Günaydın, Founders Associate at Onyx Biotech GmbH, shared a post on LinkedIn:

“This week there is a good news for people living with hemophilia A. The FDA approved Metagenomi’s application to start the first in human Phase 1/2 trial of MGX-001.

This a one time treatment designed to help the body make its own clotting factor VIII for the long term.

The trial is only beginning, and it is not know how well it works in people yet. But the approach is different from the gene therapies approved so far for hemophilia A.

Instead of delivering the gene so that it stays separate in the cell, MGX-001 is designed to insert the factor VIII gene at a specific safe location in the albumin gene, so the cell can read it with its own machinery.

Another interesting part about this treatment is how it is manufacturing.

The therapy has two parts: an AAV vector that carries the factor VIII gene, and a lipid nanoparticle that carries the mRNA for the gene-editing tool and its guide.

Two different modalities, each with its own manufacturing and purification process, and both need to meet the same quality bar.

It is a good reminder that as gene therapies get more sophisticated, the manufacturing side often grows in complexity along with them.”

Stay updated with Hemostasis Today.